School of Medicine

Showing 1-6 of 6 Results

  • Vincent Michael Alford

    Vincent Michael Alford

    Postdoctoral Research Fellow, Stem Cell Biology and Regenerative Medicine

    Current Research and Scholarly InterestsIdentifying mechanisms by which the tumor microenvironment contributes to fundamental cellular signaling pathways responsible for regulating cancer stem cells' ability to self-renewal and promote tumor relapse in patients.

  • Ash A. Alizadeh, MD/PhD

    Ash A. Alizadeh, MD/PhD

    Associate Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsMy research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.

    Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.

  • Lay Teng Ang

    Lay Teng Ang

    Instructor, Institute for Stem Cell Biology and Regenerative Medicine

    BioAs a stem cell biologist, my overall goal is to understand the mechanisms through which stem cells differentiate into progressively-specialized cell-types and to harness this knowledge to artificially generate pure populations of desired cell-types from stem cells. My work over the past 10 years has centered on pluripotent stem cells (PSCs, which include embryonic and pluripotent stem cells), which have the remarkable ability to generate any of the hundreds of diverse cell-types in the body. However, it has been notoriously difficult to guide PSCs to differentiate into a pure population of a given cell-type. Current differentiation strategies typically generate heterogeneous cell populations unsuitable for basic research or clinical applications. To address this challenge, I mapped the cascade of branching lineage choices through which PSCs differentiate into a variety of endodermal and mesodermal cell-types. I then developed effective methods to differentiate PSCs into specific lineages by providing the extracellular signal(s) that specify a given lineage while inhibiting the signals that induce the alternate fate(s), enabling the generation of highly-pure human heart, bone (Loh & Chen et al., 2016; Cell) and liver (Loh & Ang et al., 2014; Cell Stem Cell) from PSCs. In particular, I have focused on generating pure populations of liver progenitors from PSCs; these PSC-derived human liver progenitors regenerated human liver tissue, and improved the survival of, mouse models of liver failure (Ang et al., 2018; Cell Reports). My goal is to complete the preclinical development of PSC-derived liver progenitors as a potential cellular replacement therapy for liver failure. This project will be facilitated by my experience with PSC differentiation, assays of liver cell identity and function, and mouse models of liver failure.

    I earned my Ph.D. jointly from the University of Cambridge and A*STAR and was subsequently appointed as a Research Fellow, and later, a Senior Research Fellow, at the Genome Institute of Singapore. At Singapore, I was an independent group leader and received extramural funding support as PI or co-PI on three government grants. In April 2018, I moved my laboratory to Stanford University as a Siebel Investigator and Instructor at the Stanford Institute for Stem Cell Biology & Regenerative Medicine.

  • Jane Antony

    Jane Antony

    Postdoctoral Research Fellow, Stem Cell Biology and Regenerative Medicine

    Current Research and Scholarly InterestsAlthough varying degrees of progress has been made to treat the heterogenous subtypes of breast cancers, metastasis and recurrence remains a major cause of breast cancer-related deaths. My research focuses on drivers of tumor growth and testing new targets for these breast cancers to prevent metastasis and recurrence; specifically, profiling and validating genes enriched in the self-renewing tumorigenic compartment.